Open report — full analysis, no account required.
Sign up to generate reports and read filings that aren't on the open list.
Get notified when TGTX files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsTG Therapeutics reports $228M Q2 BRIUMVI revenue, raises 2026 guidance to ~$950M
Filed August 3, 2026 · Period ending August 3, 2026 · ~1 min read
Key Changes
-
high
Q2 2026 U.S. BRIUMVI revenue of $228M, up 64% year-over-year; company raised full-year 2026 total revenue guidance to ~$950M and U.S. BRIUMVI revenue to $890-905M, targeting ~$1B annualized exit run rate.
Exhibit 99.1 view on EDGAR → -
high
Phase 3 ENHANCE trial met primary endpoint, demonstrating bioequivalent exposure for single 600mg infusion versus current two-infusion initiation regimen, potentially simplifying treatment start.
Exhibit 99.1 view on EDGAR → -
high
Phase 1 subcutaneous BRIUMVI showed >60% bioavailability versus IV; fully enrolled Phase 3 trial evaluating quarterly subcutaneous dosing expects topline data year-end 2026 or early 2027.
Exhibit 99.1 view on EDGAR → -
medium
Initiated potentially registration-directed Phase 2 trial of IV BRIUMVI as maintenance therapy in myasthenia gravis and Phase 2 trial in treatment-resistant schizophrenia, expanding beyond MS.
Exhibit 99.1 view on EDGAR → -
medium
Q2 2026 net income of $7.8M, down from $28.2M in Q2 2025, reflecting increased R&D and commercialization expenses for subcutaneous manufacturing and clinical programs.
Exhibit 99.1 view on EDGAR →
Summary
TG Therapeutics delivered strong Q2 2026 results with U.S. BRIUMVI revenue of $228 million, up 64% year-over-year, and raised full-year 2026 guidance to approximately $950 million total revenue. The company is targeting an approximately $1 billion annualized U.S. revenue run rate by year-end 2026, reflecting continued commercial momentum in relapsing multiple sclerosis.
Net income declined to $7.8 million from $28.2 million in the prior-year quarter as the company invested in R&D and commercialization infrastructure. The Phase 3 ENHANCE trial met its primary endpoint, demonstrating that a single 600mg infusion achieves bioequivalent drug exposure to the current two-infusion initiation regimen. This could simplify treatment initiation and improve patient convenience.
More significantly, Phase 1 data for subcutaneous BRIUMVI showed greater than 60% bioavailability, supporting the quarterly dosing regimen now being evaluated in a fully enrolled Phase 3 trial with topline data expected year-end 2026 or early 2027. A subcutaneous formulation would offer a more convenient administration route and potentially expand the addressable market. The company also initiated clinical programs in myasthenia gravis and treatment-resistant schizophrenia, representing potential expansion opportunities beyond MS.
Section-by-Section Diff
Event · Exhibit 99.1
Added in current filing · view on EDGAR →
Second quarter 2026 total global revenue of approximately $240 million, including BRIUMVI U.S. net product revenue of approximately $228 million
Raises full year 2026 total global revenue target to approximately $950 million and raises full year 2026 BRIUMVI U.S. net product revenue target to approximately $890 - 905 million
TG Therapeutics reported Q2 2026 total global revenue of approximately $240 million, with U.S. BRIUMVI net product revenue of approximately $228 million. The company raised its full-year 2026 total global revenue target to approximately $950 million and its U.S. BRIUMVI net product revenue target to approximately $890-905 million. Management stated BRIUMVI is on track to exit 2026 at an approximately $1 billion annualized U.S. revenue run rate.
Added in current filing · view on EDGAR → · paraphrased
Announced positive pharmacokinetic (PK), pharmacodynamic (PD), safety, and tolerability data from a Phase 1 clinical trial evaluating a subcutaneous formulation of ublituximab (the active agent in BRIUMVI) as compared to IV BRIUMVI
Subcutaneous BRIUMVI demonstrated mean bioavailability of greater than 60% relative to IV administration in the Phase 1 trial
PK modeling and simulation informed by the Phase 1 bioavailability data support the quarterly subcutaneous dosing regimen that is being evaluated in the fully enrolled Phase 3 trial
Top-line Phase 3 data is expected year-end 2026 or early 2027
TG Therapeutics announced positive Phase 1 data for subcutaneous BRIUMVI, showing mean bioavailability of greater than 60% relative to IV administration. The Phase 3 trial evaluating quarterly subcutaneous dosing is fully enrolled, with topline data expected year-end 2026 or early 2027. A subcutaneous formulation could expand the addressable market by offering a more convenient administration route.
Added in current filing · view on EDGAR →
Product Revenue, net: Product revenue, net was $235.8 million and $437.1 million for the three and six months ended June 30, 2026, respectively, compared to $138.8 million and $258.5 million for the three and six months ended June 30, 2025, respectively. Product revenue, net consists primarily of net product sales of BRIUMVI in the United States, which totaled $227.7 million and $422.5 million during the three and six months ended June 30, 2026. ... Net income: Net income was $7.8 million and $27.6 million for the three and six months ended June 30, 2026, respectively, compared to net income of $28.2 million and $33.2 million for the three and six months ended June 30, 2025.
For Q2 2026, TG Therapeutics reported product revenue of $235.8 million (primarily U.S. BRIUMVI sales of $227.7 million), up from $138.8 million in Q2 2025. Net income was $7.8 million for Q2 2026, down from $28.2 million in Q2 2025, reflecting increased R&D and SG&A expenses related to subcutaneous manufacturing, clinical trials, and commercialization efforts.
Added in current filing · view on EDGAR → · paraphrased
Announced positive topline phase 1 data for subcutaneous BRIUMVI in patients with myasthenia gravis (MG)
Initiated a potentially registration-directed randomized phase 2 clinical trial evaluating IV BRIUMVI as a maintenance therapy following induction with efgartigimod in adult patients with MG
Initiated a Phase 2 clinical trial evaluating BRIUMVI in adults with treatment-resistant schizophrenia
TG Therapeutics announced positive Phase 1 data for subcutaneous BRIUMVI in myasthenia gravis patients and initiated a potentially registration-directed Phase 2 trial evaluating IV BRIUMVI as maintenance therapy in MG. The company also initiated a Phase 2 trial evaluating BRIUMVI in treatment-resistant schizophrenia. These programs represent potential expansion opportunities beyond multiple sclerosis.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Aug 4, 2026 · How we verify